FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3093417962> ?p ?o ?g. }

• W3093417962 endingPage "3021" @default.
• W3093417962 startingPage "3021" @default.
• W3093417962 abstract "The approval of trastuzumab emtansine (T-DM1) was conducted without pertuzumab as previous therapy. Efficacy data on T-DM1 following pertuzumab treatment are therefore limited. This study explores this issue in a real-world setting. Within the prospective PRAEGNANT (Prospective Academic Translational Research Network for the Optimization of the Oncological Health Care Quality in the Advanced Setting) metastatic breast cancer registry (NCT02338167), patients in all therapy lines receiving any kind of treatment were eligible for inclusion. This report describes patient characteristics and progression-free survival (PFS) in human epidermal growth factor receptor 2 (HER2)-positive patients receiving T-DM1 after pertuzumab treatment. Seventy-six patients were identified, 39 of whom received T-DM1 as second-line therapy, 25 as third-line, and 12 as fourth-line therapy or higher. Pertuzumab was mostly administered as a first-line treatment (n = 61; 80.3%). The median PFS in all patients was 3.5 months (95% CI: 2.8–7.8); in second-line treatment, 7.7 months (95% CI: 2.8–11.0); in third-line, 3.4 months (95% CI: 2.3–not reached (NR)); and in fourth-line therapy or higher, 2.7 months (95% CI: 1.2–NR). T-DM1 was mainly administered second-line after pertuzumab, but also in more heavily pretreated patients. The PFS in higher therapy lines appears to be shorter than in second-line." @default.
• W3093417962 created "2020-10-22" @default.
• W3093417962 creator A5000257757 @default.
• W3093417962 creator A5003405177 @default.
• W3093417962 creator A5011687402 @default.
• W3093417962 creator A5013142812 @default.
• W3093417962 creator A5014726448 @default.
• W3093417962 creator A5015562881 @default.
• W3093417962 creator A5017728105 @default.
• W3093417962 creator A5021298305 @default.
• W3093417962 creator A5023008141 @default.
• W3093417962 creator A5028882183 @default.
• W3093417962 creator A5030131864 @default.
• W3093417962 creator A5031666050 @default.
• W3093417962 creator A5032246802 @default.
• W3093417962 creator A5035775338 @default.
• W3093417962 creator A5035799597 @default.
• W3093417962 creator A5038957171 @default.
• W3093417962 creator A5042564261 @default.
• W3093417962 creator A5044421523 @default.
• W3093417962 creator A5045891981 @default.
• W3093417962 creator A5048706345 @default.
• W3093417962 creator A5050467390 @default.
• W3093417962 creator A5052040947 @default.
• W3093417962 creator A5053845865 @default.
• W3093417962 creator A5058627245 @default.
• W3093417962 creator A5067146231 @default.
• W3093417962 creator A5070338465 @default.
• W3093417962 creator A5072762948 @default.
• W3093417962 creator A5086791040 @default.
• W3093417962 creator A5088637879 @default.
• W3093417962 creator A5089392438 @default.
• W3093417962 date "2020-10-17" @default.
• W3093417962 modified "2023-10-07" @default.
• W3093417962 title "Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab" @default.
• W3093417962 cites W2000612276 @default.
• W3093417962 cites W2012784647 @default.
• W3093417962 cites W2095861620 @default.
• W3093417962 cites W2110444464 @default.
• W3093417962 cites W2120661754 @default.
• W3093417962 cites W2123591186 @default.
• W3093417962 cites W2137228442 @default.
• W3093417962 cites W2141393790 @default.
• W3093417962 cites W2159967578 @default.
• W3093417962 cites W2318605753 @default.
• W3093417962 cites W2330814896 @default.
• W3093417962 cites W2379981061 @default.
• W3093417962 cites W2414879736 @default.
• W3093417962 cites W2443444708 @default.
• W3093417962 cites W2551315898 @default.
• W3093417962 cites W2560406314 @default.
• W3093417962 cites W2582248920 @default.
• W3093417962 cites W2616160160 @default.
• W3093417962 cites W2616596696 @default.
• W3093417962 cites W2619710211 @default.
• W3093417962 cites W2624590002 @default.
• W3093417962 cites W2726659407 @default.
• W3093417962 cites W2734122054 @default.
• W3093417962 cites W2752816555 @default.
• W3093417962 cites W2765167427 @default.
• W3093417962 cites W2768649895 @default.
• W3093417962 cites W2773718170 @default.
• W3093417962 cites W2774227900 @default.
• W3093417962 cites W2776036154 @default.
• W3093417962 cites W2789588170 @default.
• W3093417962 cites W2792063304 @default.
• W3093417962 cites W2905960639 @default.
• W3093417962 cites W2948405934 @default.
• W3093417962 cites W2981788107 @default.
• W3093417962 cites W2995808512 @default.
• W3093417962 cites W2996630100 @default.
• W3093417962 cites W3029441570 @default.
• W3093417962 cites W3030461309 @default.
• W3093417962 cites W3043096450 @default.
• W3093417962 cites W4252091777 @default.
• W3093417962 doi "https://doi.org/10.3390/cancers12103021" @default.
• W3093417962 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7603111" @default.
• W3093417962 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33080911" @default.
• W3093417962 hasPublicationYear "2020" @default.
• W3093417962 type Work @default.
• W3093417962 sameAs 3093417962 @default.
• W3093417962 citedByCount "6" @default.
• W3093417962 countsByYear W30934179622021 @default.
• W3093417962 countsByYear W30934179622022 @default.
• W3093417962 countsByYear W30934179622023 @default.
• W3093417962 crossrefType "journal-article" @default.
• W3093417962 hasAuthorship W3093417962A5000257757 @default.
• W3093417962 hasAuthorship W3093417962A5003405177 @default.
• W3093417962 hasAuthorship W3093417962A5011687402 @default.
• W3093417962 hasAuthorship W3093417962A5013142812 @default.
• W3093417962 hasAuthorship W3093417962A5014726448 @default.
• W3093417962 hasAuthorship W3093417962A5015562881 @default.
• W3093417962 hasAuthorship W3093417962A5017728105 @default.
• W3093417962 hasAuthorship W3093417962A5021298305 @default.
• W3093417962 hasAuthorship W3093417962A5023008141 @default.
• W3093417962 hasAuthorship W3093417962A5028882183 @default.
• W3093417962 hasAuthorship W3093417962A5030131864 @default.
• W3093417962 hasAuthorship W3093417962A5031666050 @default.

• next